Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Next Previous
Search
Drug Profile

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Alternative Names: 5T4 x CD3 DART; DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; JNJ-9383; MGD 015; MGD-15; ROR1xCD3 DART

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen modulators; Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 13 receptor modulators; Programmed cell death 1 receptor antagonists; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 18 Nov 2020 TRIANNI has been acquired by Abcellera
  • 06 Dec 2018 MacroGenics in-licenses the Trianni Mouse transgenic mouse platform technology from Trianni

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top